ACME UNITED CORP - 10-Q Summary (Period Ended Sep 30, 1995)
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for ACME UNITED CORPORATION for the period ended September 30, 1995. The company operates in consumer and medical product sectors, with significant foreign operations in Europe. The report covers the three and nine months ended September 30, 1995, compared to the same periods in 1994.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 1995 | 9 Months Ended Sep 30, 1994 |
|---|---|---|
| Net Sales | $41,204,804 | $40,110,339 |
| Net Income (Loss) | $7,354 | $85,434 |
| Income Per Share | $0.00 | $0.03 |
| Gross Profit Margin | 28% | 28% |
| Cash and Equivalents (End of Period) | $180,313 | $220,981 |
| Net Cash Used by Operations | ($1,412,929) | ($906,789) |
| Total Debt (Current + Long Term) | $20,865,782 | $18,387,659 |
| Working Capital | $22,423,000 | $21,035,000 |
Material Changes vs. Prior Period
- Revenue: Net sales increased by 3% ($1.09 million) for the nine-month period. Consumer operations grew 5%, while medical operations declined 3% due to volume decreases in wound care products.
- Profitability: Net income dropped significantly to $7,354 from $85,434 in the prior year. The third quarter specifically recorded a net loss of $166,330.
- Cash Flow: Operating cash flow turned more negative, with net cash used by operations increasing to $1.41 million from $906,789. This was driven by a $2.27 million increase in accounts receivable and a $465,927 decrease in accounts payable.
- Expenses: Interest expense rose by $325,000 due to higher borrowings and interest rates. Selling, general, and administrative expenses increased slightly by 1%.
Outlook, Risks, and Unusual Items
- Unusual Items: The company incurred a $210,000 charge in the third quarter related to the unsuccessful relaunch of the OPCO Line of I.V. therapy products, including inventory and licensing rights write-offs.
- Restructuring Risk: Due to continued poor performance at the German subsidiary (Peter Altenbach & Son GmbH), management is evaluating restructuring alternatives for European operations, which may result in future charges.
- Liquidity: The company maintains a $13 million U.S. revolving line of credit expiring in March 1997. Management believes current cash balances and credit facilities are sufficient to meet 1995 commitments.
- Guidance: Capital expenditures for the full year 1995 are expected to be approximately $1,000,000.
Investor Verification Checklist
- Verify the status and potential financial impact of the restructuring evaluation for the German subsidiary.
- Confirm the collectability of the $2.27 million increase in accounts receivable.
- Monitor the performance of the medical operations segment, which is experiencing volume declines.
- Review the terms and renewal status of foreign overdraft arrangements expiring in 1995.
- Assess the sustainability of the $13 million revolving credit line and the company's ability to service increased debt levels.